Skip to content
To the full analysis

Shenzhen Salubris Pharmaceuticals stock: balance sheet and debt

002294.SZ
$4.47Closing price of 12 Nov 2026MEQIRI Score 52 out of 100

Shenzhen Salubris Pharmaceuticals has a debt to equity ratio of 0.08 and an interest coverage of 30.8x.

Debt / Equity
0.08
Interest coverage
30.8x
Current ratio
2.28
Cash & equivalents
$463.52M
Total assets
$1.7B
Equity ratio
81.3%
Goodwill
$32.92M
Plus intangible assets of $494.55M
Net debt
−$356.88M
More cash than debt

Total assets and equity ratio

How large the balance sheet of Shenzhen Salubris Pharmaceuticals Co., Ltd. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2006$23.79M$127.27Knot split out67.1%$1.05M
2007$38.38M$63.63Knot split out57.0%−$56.85K
2008$61.28Mnot reported separatelynot reported separately64.3%$1.79M
2009$265.73M$1.72Mnot split out91.6%−$174.49M
2010$326.15M$7.45Mnot split out85.8%−$150.81M
2011$366.68M$23.36Mnot split out87.3%−$133.39M
2012$447M$25.38Mnot split out87.5%−$143.78M
2013$546.36M$77.88Mnot split out86.0%−$134.1M
2014$692.24M$157.08Mnot split out82.1%−$159.18M
2015$807.84M$193.13M$13.07M87.2%−$144.78M
2016$979.89M$201.28M$13.07M83.6%−$257.75M
2017$1.03B$216.34M$13.07M89.7%−$247.28M
2018$1.19B$331.93M$57.11M86.9%−$150.42M
2019$1.16B$315.62M$55.47M86.2%−$155.51M
2020$1.04B$310.25M$13.07M80.6%−$102.3M
2021$1.39B$314.65M$13.07M87.0%−$483.45M
2022$1.46B$336.68M$9.08M81.8%−$420.21M
2023$1.41B$393.91M$1.64M85.7%−$218.27M
2024$1.57B$423.76M$1.64M83.6%−$260.2M
2025$1.7B$527.47M$32.92M81.3%−$356.88M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2006$997.42K$15.97M$2.05M0.13
2007$5.09M$21.89M$5.03M0.23
2008$7.84M$39.43M$9.63M0.24
2009$174.49M$243.16M$00
2010$150.81M$279.42M$00
2011$133.39M$319.77M$00
2012$143.78M$390.5M$00
2013$134.1M$469.29M$00
2014$159.18M$566.79M$00
2015$153.78M$688.26M$9M0.01
2016$266.75M$803.86M$9M0.01
2017$251.78M$907.72M$4.5M0
2018$186.72M$998.49M$36.3M0.04
2019$197.94M$973.19M$42.43M0.04
2020$161.92M$826.05M$59.62M0.07
2021$494.26M$1.2B$10.81M0.01
2022$449.72M$1.19B$29.51M0.02
2023$226.15M$1.2B$7.88M0.01
2024$278.82M$1.31B$18.62M0.01
2025$463.52M$1.34B$106.64M0.08

Data status and sources

Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Currency
Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Jul 2024)
  • Valuation signal Overvalued since 7 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy